“Unethical Cancer Study Designs: Why Clinical Trials Aren’t Always Best for Patients.” oncologynewscentral.com/article/unethi…

This is an updated results data of BCMA CAR-T and BCMA BsAb with updated data from recent presentations/publications based on few requests I got #mmsm ✅Updated data for Elranatamab looks great ✅In areas with equal access to CAR-T: no role for ide cel ✅Excellent BsAb data

AMAZING!!! The second you whiff semaglutide you immediately have improvement on proxy measures of tobacco use!!! Sarcasm intended since this is a negative outcome - too much confounding Also EHR data cannot speak to smoking cessation Epic fail of peer & editorial review

Pair this study with this excellent JAMA Internal Medicine perspective on the "too fast" bias where groups separate way faster than biologically plausible this is a dead giveaway groups are not the same despite best efforts to adjust Vinay Prasad MD MPH jamanetwork.com/journals/jamai…

You know when Drug is not blockbuster ( or even close to being that ) when it is keep getting defended in repeated correspondence The Lancet Oncology When the Sun 🌞 shines , do we need torch to see it ? Putting both sides . Readers to choose wisely. Any comments Vinay Prasad MD MPH

“I would teach a medical student something and it seemed to trigger a lightbulb in their head, and I thought, I wish someone else had told me about that, so I just started sharing more widely.” Profile: Aaron Goodman - “Papa Heme” aka Papa Heme Common Sense Oncology UC San Diego thelancet.com/journals/lanha…

Aw, thanks! That was nice of The Lancet Haematology to feature me!

Happy to see this piece on Aaron Goodman - “Papa Heme” in The Lancet Haematology. A well deserved accolade. Greatness isn’t defined by the n of papers/trials you have, but by taking good care of pts, and being a great husband/father/friend. And that’s what Aaron is! thelancet.com/journals/lanha…

Thanks, I am so not humbled Manni thanks for being my best friend !

Actually, Aaron has many papers/trials too. I am biased, but my favorite paper of his one we wrote together in which we highlighted the epidemic of over-treatment of myeloma and its precursor states. Heres a non paywalled link to it: drive.google.com/file/d/1wPINXf…

Patients with myeloma are often over treated. Read our paper in Nature Reviews Clinical Oncology Diana Romero

NEJM is the best journal in our field. I did expect a more nuanced editorial and was a little disappointed to see this. Belantamab is indeed defying expectations and turning out to be better than expected. However.... ⭐️The fact that quality of life was not reported as being

Literally just about anyone would write an editorial if asked by NEJM. Can’t they find one doc to write the editorial who doesn’t take money from the company whose drug and trial are being editorialized?

特定の製薬企業から顧問料を受けてアドバイザーを務めている人物がNEJMのように臨床医に影響力を持つ雑誌に論説を寄稿することについての警鐘をした文章。薬剤の有用性ばかりが強調されてQOLを損ねる有害事象などが過小評価されかねない、と。／NEJM

Manni Mohyuddin I am left wondering what is the point of this editorial? I struggled to find any interesting analysis or insights, it's merely a repetition of what's already stated by the authors in the discussion section. Editorials should be appraising or contextualising, not paraphrasing.

This study (40 patients each arm) is a good representation of how a small sample size can lead to an unreliable estimate. A PFS difference of 13 months with ixazomib is unlikely to be replicated in phase 3, and inconsistent with what ixa has shown! tinyurl.com/bdex6nxe

This is a pervasive problem. Why can’t journals ask for editorials from people who don’t get money from the same company whose drug is being discussed? jnccn.org/downloadpdf/vi…

Aaron Goodman - “Papa Heme” For me, this drug is dead on arrival because eye toxicity is awful for anyone, really quality of life limiting and dangerous. In the real world lots of patients have weird insurance, Medicaid so quick access to top flight ophthalmologists interested in these pts is too limited

👌🏽👌🏽👌🏽 To say that belantamab does not impair quality of life is ridiculous. It speaks to the imperfection of how we assess and report quality of life. Unfortunate that some obvious truths have to be clearly pointed out this way. Aaron Goodman - “Papa Heme”

Manni Mohyuddin 🇨🇦🧙‍♂️ (🦍/🐒) The survival of the control arm was less than contemporary trials of similar agents, which could be from patient selection, lack of blinding, inadequate subsequent care or other unknown factor, better?